A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Key outcomes of all-cause mortality and portal hypertension complications are improved with SGLT2inhibitors, new research ...

Results showed that 62.9% of patients on Ozempic saw a reduction in liver inflammation, compared to 34.3% on placebo.

Semaglutide, a GLP-1 receptor agonist sold under brand names Wegovy and Ozempic, is approved for weight loss and blood sugar ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Too Much Chicken? New Research Finds Link to Increased Risk of Early DeathA recent study published in the journal Nutrients ...

Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Frederic Cren, Chief Executive Officer of Inventiva, ...

An international study led by the director of Virginia Commonwealth University’s liver institute suggests that the substance in Ozempic and Wegovy can halt and even reverse a ...

The report emphasized the progress of pegozafermin through Phase 3 clinical development, with positive results from Phase ...

Cedars-Sinai investigators have discovered a signaling interaction between two proteins in cells that controls fat ...

Zurich (Switzerland), May 5, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today ...